Citius Pharmaceuticals Inc vs Cassava Sciences Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Cassava Sciences Inc is far larger — about 2.4× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FLNA | |
|---|---|---|
Market Cap | $20.01M | $47.75M |
Sector | Health | Health |
52-Week High | $1.82 | $4.64 |
52-Week Low | $0.48 | $0.87 |
Enterprise Value | $16.23M | -$34.93M |
Trailing returns across standard periods
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →